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Abstract Cell based therapies are of increasing interest in the treatment of systemic lupus due to
their potential for long term suppression or cure of disease. Twomethods for stemcell transplantation
are currently being investigated/performed for treatment of lupus. Autologous hematopoetic stem
cell transplantation is used in patients refractory to standard therapy. Themorbidity andmortality of
the procedure limit its use to select patients. Results indicate 50% long term disease free survival. The
technical difficulty of the procedure requires it to be performed only in experienced centers.
Mesenchymal stem cell transplants are a new emerging therapy for the treatment of lupus. Studies in
murine models of lupus provide evidence of efficacy with safety. Limited uncontrolled trials in
humans provide evidence of efficacy as well. Controlled trials are needed to assess the efficacy of
both these therapies compared to standard therapy.
Published by Elsevier Inc. Open access under CC BY-NC-ND license.an Lucas Street, Suite 912, Ch
u (G. Gilkeson).
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329Hematopoetic and mesenchymal stem cell transplantation1. Introduction
Systemic lupus erythematosus (SLE) is a devastating auto-
immune disease that targets multiple organ systems. SLE is
characterized by autoantibody production, immune complex
(IC) formation, chronic inflammation and end organ damage.
Although the etiology of this disease is not completely
understood, a great deal of evidence suggests that persis-
tent immune cell activation due to inadequate immune
surveillance/suppression is associated with the development
of SLE [1,2]. Currently, treatment options for SLE are limited
with notable side effects, thus significant effort is being
expended in order to develop more effective therapeutic
strategies [3]. Most treatment options for autoimmune
diseases, including SLE, have a broad impact on the immune
system and are not targeted to specific immune dysfunctions
[4]. These types of therapeutics can interfere with the
necessary functions of the immune system resulting in
infections and malignancies, thus development of more
specifically targeted therapies are of particular interest
[3,4].
Studies in lupus prone mouse strains confirmed that
systemic lupus is primarily a bone marrow derived disease as
reconstituting a normal mouse with lupus derived bone
marrow led to disease, while reconstituting a lupus mouse
with marrow from a non-lupus strain resulted in prevention/
resolution of disease [5,6]. Subsequently, in lupus patients
receiving allogeneic bone marrow transplants for hemato-
logic malignancies, lupus disease remission was often noted
[7]. These findings in mice and humans suggested that stem
cell or bone marrow abnormalities underlie lupus pathogen-
esis and that bone marrow/stem cell transplantation may
serve as a new therapeutic approach in lupus. Recently,
there is increasing interest in a different type of stem cell
transplant in autoimmune diseases, including lupus. This
approach uses mesenchymal stem cells rather than hemato-
poietic stem cells. Early uncontrolled studies suggest that
this approach is also a promising therapeutic area for
investigation in lupus [8]. This review will summarize the
published literature to date on the success of bone marrow/
stem cell transplant approaches for the treatment of lupus.2. Hematopoeitic bone marrow/stem cell
transplantation
As noted above, there are a number of case reports of lupus
patients and patients with other autoimmune diseases receiving
allogeneic or autologous bone marrow transplants for treat-
ment of malignancies [7]. These reports noted that often
disease was put into remission for extended periods indicating a
therapeutic benefit of the procedure. The immediate mortality
rates and side effects of allogeneic and autologous bone
marrow transplants, however, rendered allogeneic/autologous
bone marrow transplantation's risk to benefit ratio too high for
consideration as therapy.
The advent of bone marrow stem cell transplants, with less
treatment related mortality and side effects, provided a new
avenue for therapeutic consideration in lupus patients [9]. In
attempts to make the procedure even safer, investigators
began using non-myeloablative conditioning regimens to lowerthe risk of infection and treatment relatedmorbidity/mortality
[10–12]. Reports in the literature indicate that over 200
patients received autologous stem cell transplants as therapy
for their lupus [12]. In all cases, patients were refractory to
aggressive standard of care measures. The response rate is
similar between the reports with the majority of the patients
coming from the European Bone Marrow Transplant group (n=
85) and a single center experience at Northwestern United
States (n=50) [12]. The conditioning regimen used at the
different institutions varied, though cyclophosphamide and
anti-thymocyte globulin were the most common agents used.
The results were similar as far as efficacy is concerned
between the institutions with approximately 50% achieving
5 year relapse free survival, with many of all medications
[10–12]. In contrast, overall mortality varied significantly
from 16 to 29% considering only studies with 10 or more
patients. Transplant related mortality varied from 4 to 25%
[10–12].
The treatment effect of the procedure is not from the
stem cells, but the conditioning regimen that “resets” the
bone marrow. Eliminating autoreactive lymphocytes with
reconstitution of the immune system with naïve cells, allows
the immune system to start over with a delay or prolonged
interval to reemergence of autoimmunity [12]. The stem
cells decrease the time of marrow recovery and infection
risk.
A problem with autologous stem cell transplantation is
patient selection. Due to the high risk of the procedure itself,
only patients that have failed all conventional therapy are
candidates. However, to survive the procedure, patients cannot
have significant end organ damage. This difficulty in identifying
the right patients for this procedure led to the failure of an NIH
funded trial of autologous stem cell transplantation in lupus to
enroll sufficient patients [12].
In summary, autologous bone marrow stem cell transplan-
tation following non-myeloablative conditioning results in
prolonged remissions in 50% of patients. Although procedure
mortality rates remain significant, in selected patients it is a
viable alternative. It must be emphasized, however, that the
procedure should only be done in institutions with significant
experience in performing the procedure, in consultation with
experts in the management of severe lupus. Hopefully, newer
conditioning regimens will be developed that will further
lower the procedure mortality rate making it a treatment
option for more patients with less severe disease.3. Mesenchymal stem cell transplantationA population of non-hematopoietic stem cells, mesenchymal
stem cells (MSC), are of increasing interest as a therapeutic
option for many autoimmunity diseases. MSCs are a multi-
potent stem cell population that can differentiate into os-
teoblasts, chondrocytes, and adipocytes [13]. A desirable prop-
erty of MSCs for therapeutic use is that they are a readily
available stem cell population, as they can be derived from
various sources such as bone marrow, umbilical cords, adipose
tissue, and dental pulp [14]. In addition to the ready availability
of MSCs, they havemany known immuno-modulatory properties
that would be predicted to be effective in developing a cellular
therapy for SLE, along with other autoimmune diseases.
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It is clear that MSCs are effective immunosuppressive cells,
however, the mechanisms by which MSCs are able to elicit
such effective immunosuppression are unclear, though they
involve both the innate and adaptive arms of the immune
system. Previous studies revealed suppressive functions of
MSCs that include inhibiting the activity of T cells, B cells,
natural killer (NK) cells, and antigen presenting cells (APC)
[15]. MSCs may modulate the immune system by a variety of
methods including, but not limited to, the secretion of
anti-inflammatory cytokines, expansion of regulatory T
cells, and down regulation of co-stimulatory molecules on
APCs [16]. The dissection of these mechanisms by which
MSCs suppress disease provides valuable insight into how this
stem cell subset can be best utilized in cell therapy as well
as insight into the pathogenesis of disease.
Although MSCs are able to suppress most cells of the
immune system they are unable to do so without proper
activation. Activation of MSCs occurs when they are within the
appropriate pro-inflammatory cytokine microenvironment.
Upon transfer, MSCs home to sites of inflammation (Fig. 1).
MSCs express a wide variety of chemokine receptors such as
CCR1, CCR3, CCR7, CCR8, CCR10, CCR11, CXCR3, CXCR4, and
CXCR6 [17]. Furthermore, these chemokine receptors have
ligands that are specific for certain tissues. Not all MSCs in a
population will possess the same combination of chemokine
receptors [18]. This heterogeneity of the MSC population is
what gives MSCs the potential to home to diverse sites to
perform their immunemodulatory functions [19,20]. Concerns
about trapping of MSCs in remote organs post transplantation
occurred when studies inmice showed accumulation of cells in
the lung [21]. Human MSCs, however, seem to act differently
than those of mouse in that they are not retained in the lung
permanently [22]. Human MSCs when transplanted into miceActivated MSC 
Treg 
T cell 
B cell 
Figure 1 Suppression of immune cells by mesenchymal stem cells
homing mechanisms. Upon arrival to the site of inflammation, MSC
IL1β) produced by local immune cells. Activated MSCs produce variou
players such as T cells, B cells, and APCs. MSCs also generate Tregs
broad immuno-modulatory capabilities of MSCs are effective at dam
MSCs make them a promising cell therapy target for autoimmune diare trapped initially in the lung. Yet, soon after, MSCs were
cleared and found in other organs. In fact, MSCs can be found
up to a year post transfer in the skin, lung, kidney, liver, and
thymus when these organs are analyzed via RT-PCR [23].
Once MSCs have homed to an inflamed tissue, they
encounter the microenvironment that is essential to the
development of their suppressive properties. Cytokines
recognized to enhance the immuno-modulatory properties
of MSCs include IFNγ, IL1β, and TNFα [24]. These cytokines
are prevalent in areas of heightened inflammation where
MSCs home upon transplantation. Numerous groups have
shown that IFNγ is required to initiate the suppressive
efficacy of MSCs [25,26]. Without the IFNγ induced activa-
tion of MSCs, they were less efficient suppressors of immune
responses in graft versus host disease (GVHD) [25]. Further-
more, when MSCs were transferred into mice deficient in
IFNγ the MSCs were unable to suppress GVHD [25]. Although
IFNγ clearly is required for the heightened suppressive
functions of MSCs, other pro-inflammatory cytokines have an
additive effect on MSCs. MSCs activated with TNFα or IL1β, in
addition to IFNγ, were significantly more immune suppressive
than MSCs cultured with any one cytokine [24]. Furthermore,
upon activation, MSCs produce various chemokines to attract
immune cells. Among these chemokines are CXCL9 and
CXCL10. Both of these chemokines are attractants for T cells
and will draw these cells to the MSCs [24]. Once T cells are
within range, MSCs can then suppress these activated cells.
Mixed cytokine microenvironments are common at sites of
inflammation, thus MSCs, once homed to the area of interest,
will likely experience the appropriate cytokine milieu to
become activated for suppression. As aforementioned MSCs
may home to, and accumulate in, organs that are not the
target of disease. Thus along with the secretion of chemo-
attractants MSCs can also produce anti-inflammatory cyto-
kines by which they can elicit their suppressive effects from aNon-activated MSC 
APC 
. MSCs travel to injured/inflamed tissues by chemokine induced
s encounter appropriate activation cytokines (IFNγ, TNFα, and
s cytokines/proteins that effectively shut down several immune
which contribute to suppressing the inflammation. Overall, the
pening both local and systemic inflammation. The properties of
seases such as SLE.
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these suppressive cytokines. In vivo studies have shown the
production of TSG-6 by MSCs that have accumulated in the
lung has been sufficient to provide anti-inflammatory effects
in the murine heart and cornea injury models [27,28].
Upon homing and activation, MSCs suppress the activation
and proliferation of various immune cells. The interaction of
MSCs and other immune cells is not a one way street
however, as the immune cells also interact and influence the
properties of the MSCs. The interactions of MSCs and T cells
are the best defined mechanism by which MSCs influence the
immune system. T cells are nearly ubiquitous at sites of
inflammation and, in the instance of a type 1 inflammatory
response, significant amounts of IFNγ are made by Th1 cells
[29]. Due to their ability to produce IFNγ, Th1 cells play an
important role in the activation of MSCs. Once activated,
MSCs can effectively suppress proliferation of T cells in
mixed lymphocyte reactions, when added at the initiation of
culture or when added to an ongoing cell culture [30]. MSCs
achieve T cell suppression by both direct and indirect
methods. MSCs can produce various inhibitory cytokines or
signaling molecules capable of inhibiting T cell responses.
MSCs produce IL10, an anti-inflammatory cytokine, and induce
regulatory APCs that assist in the inhibition of T cell activation
[30]. A vital immunosuppressive protein produced by MSCs is
inducible nitric oxide synthase (iNOS). iNOS facilitates the
production of NO, which in turn, suppresses the activation of T
cells putting them in a reversible anergic state [24]. Pros-
taglandin E2 (PGE2) and indoleamine 2,3-dioxygenase (IDO)
are proteins also produced by MSCs that elicit an inhibitory
effect on T cells as well as other immune players. MSCs readily
produce these proteins upon activation and they have a
synergistic effect on the suppression of T cells [31–33]. MSCs
also promote the expansion of regulatory T cells (Tregs) [34]. A
mechanism by which MSCs induce Tregs is by the productions
of IDO [35]. The expansion of the Treg population, along with
the production of T cell inhibitory proteins, are methods by
which MSCs are able to effectively mold a homeostatic
immune environment through T cell regulation.
B cells play an important role in autoimmune diseases. In
diseases such as lupus, B cells produce autoantibodies to an
array of nuclear antigens, present antigen to T cells, secrete
key cytokines and help to establish ectopic lymphoid activity,
thus exacerbating disease [36]. MSCs impact B cells by
inhibiting proliferation of B cells. Moreover, B cell differenti-
ation and their chemotactic properties are also suppressed
when cultured in the presence of activated MSCs [37]. Recent
studies into the mechanism by which MSCs dampen B cell
immune responses showed that the suppression is primarily
achieved by soluble factors produced by MSCs. Contradicting
the in vitro conclusions of MSCs' suppressive influence on B
cells are in vivo studies showing the inability of MSCs to
decrease auto-antibody production and expansion of plasma
cells [37,38]. Although this in vivo expansion of B cells could
potentially exacerbate disease in lupus pronemice, significant
histological improvements suggest that MSCs are still func-
tional in ameliorating disease [37].
Peripheral tolerance, which is often broken in autoim-
mune diseases, is facilitated by APCs. Professional APCs
include three main cell types: dendritic cells (DC), macro-
phages, and B cells. All of these cell types uptake and
present antigen along with proper co-stimulation for T cells.T cells can then elicit an adaptive immune response. In lupus,
presentation of self-antigens occurs via APCs resulting in a
self-directed immune response by T cells [39]. MSCs interfere
with antigen presentation of DCs, which are major activators
of T cells [39]. Antigen presentation is hindered by MSCs by
preventing the TNFα induced maturation of DC. In addition to
interference with antigen presentation, MSCs can also prevent
the migration of DC. Chemokine receptor CCR7, whose ligand
is present in the lymph nodes, and the epithelial anchoring
protein E-cadherin play an important role in the migration of
DCs to the lymph node. Hindrance of DC migration to lymph
nodes is due to decreased expression of CCR7 and increased
expression of E-cadherin, essentially stalling the DC from
reaching the lymph node for proper T cell antigen presenta-
tion [39]. Without antigen presentation/co-stimulation to
activate the T cell, an adaptive T cell immune response will
not occur. In autoimmunity, this type of immune control can
inhibit auto-reactive T cells from being activated towards a
self-antigen.
MSCs have unique attributes beyond their suppressive abil-
ities that make them attractive for cellular therapy. To begin,
MSCs are immune privileged by avoiding, at least at first,
allo-reaction [40]. Therefore the hurdle of finding an MHC
compatible donor is not a concern in MSC transplantation.
Unlike hematopoetic stem cells (HSC), MSCs can double 40–50
times allowing them to be cultured and expanded to numbers
suitable for transplantation from small initial cell numbers [41].
Lastly, MSCs home to areas of tissue injury [42]. These areas are
the zones in which excessive inflammation is occurring. Upon
transplantation, MSCswill home towards areas of inflammation,
become activated in the pro-inflammatory environment, and
exert their suppressive effects on the surrounding host immune
cells.3.2. MSC and lupus
The systemic autoimmunity seen in SLE is a combination of
regulatory mechanisms gone awry, leading to a disease that
has numerous components contributing to disease manifesta-
tions. Because of this multi-cell dysregulation, SLE treatments
are difficult to develop because they require broad dampening
of immune responsiveness often leading to undesirable side
effects. New therapeutics that inhibits autoimmune cells,
while allowing the rest of the immune system to still function,
would be a major step forward. This potential of targeted
cellular therapy is the attraction of MSCs for cellular therapy.
MSCs have the in vitro and in vivo ability to promote
immuno-modulatory effects without the infectious conse-
quences often seen with extensive immune suppression.
Because of MSC's multi-cell suppressive capabilities, they
have the potential to be a good cellular therapy for SLE.
To date, numerous studies have examined the effects of
MSC transplantation on SLE and other autoimmune diseases. In
murine collagen-induced arthritis, MSCs have shown con-
flicting results regarding their efficacy in disease prevention.
Several studies showcase the effectiveness of MSC after the
establishment of arthritic disease [43,44]. However, other
studies with the CIA model have shown that no immunosup-
pressive effects are seen with MSC injection [45,46]. Regard-
less of the varied results seen in the CIA model of autoimmune
disease, bothmurine and human in vivo studies suggested that
332 E. Collins, G. GilkesonMSCs have the potential to be a beneficial treatment option
for SLE. Allogeneic non-lupus prone MSC transplantation into
murine models of lupus prolonged life and decreased disease
severity, marked by reduction of serologic markers, glomer-
ular immune complex deposition, and lymphocyte infiltration
[37,47]. The profound impact of murine MSCs on SLE leads to
the examination of the effects of human MSC (hMSC) trans-
plantation into these same murine models. Upon transplanta-
tion into lupus prone mice, hMSC were also able to decrease
disease severity [48,49]. Mice receiving hMSC also experi-
enced reduced proteinuria, renal injury, anti-dsDNA anti-
bodies, and pro-inflammatory cytokines. These mice also
experienced an increase in their peripheral Treg population.
Collectively, these murine studies suggested MSC transplan-
tation to be a potential treatment in SLE patients.
In vitro studies with hMSC showed that they are effective in
immune suppression. However, studies examining MSCs from
SLE patients have suggested that they are not as effective as
MSCs from normal patients [34]. SLE MSCs have various
abnormalities such as slower growth in culture and early
signs of senescence suggesting that they are not as likely to be
efficacious as MSCs from healthy individuals [50,51]. Two
female lupus patients receiving autologous MSCs experienced
an increase in circulating Tregs and decreased peripheral
blood lymphocyte function [52]. However, these two patients
did not experience any beneficial effects on disease severity.
These results imply that SLE-MSCs may lack in suppressive
function in comparison to MSCs from non-lupus patients.
On the basis of the positive outcomes seen in SLEmice upon
MSC transplantation, studies began investigating the effects of
allogeneic MSC transplantation on patients with treatment
refractory SLE. One study treated four cyclophosphamide
(CTX)/glucocorticoid treatment-refractory SLE patients with
allogeneic bone marrow derived MSCs (BM-MSC) and found
that all patients experienced 12–18 months of disease
remission and improved SLEDAI score with no serious adverse
events from the treatment. Reduction of disease was marked
by improved serologic markers and renal function [8]. A larger
study group of 15 patients with SLE refractory to treatment
received allogeneic BM-MSC transplants [53]. All patients
experienced clinical improvement following treatment with
decreases in proteinuria and anti-dsDNA levels. Both of these
studies demonstrated the potential beneficial results of
BM-MSC transplantation in human SLE. In all these patients,
however, they continued on standard therapy with the
possibility that the response seen was due to a delayed
response to standard treatment rather than due to the MSCs.
Umbilical cord derived MSC (UC-MSC) also demonstrated
a significant therapeutic effect in animal studies in lupus. To
examine the effectiveness of UC-MSC in human disease, 16
patients with refractory SLE received UC-MSC transplanta-
tion [54]. Results from this study showed that UC-MSCs were
successful in reducing SLE disease severity with improved
disease activity scores. Patients also had significant im-
provements in serum titers of ANA and anti-dsDNA, increased
serum albumin, and complement C3. In addition to the
clinical improvement of disease, patients experienced an
increase in peripheral Tregs along with a restoration of the
Th1/Th2 cytokine balance.
Although these uncontrolled studies of MSCs in the
treatment of lupus have shown promise, MSC have also
been used in two large randomized controlled trials forGVHD and Crohn's disease. 55 patients with steroid-resistant
acute GVHD received bone marrow derived MSC from various
donors. No side effects were seen during or immediately
after the infusion of the allogeneic MSC infusion. 30 patients
of the 55 had a complete response upon MSC infusion while
another 9 showed improvement [55]. Another study of 10
Crohn's disease patients who were refractory to current
medical treatments received autologous MSC. Their autolo-
gous MSCs were equally suppressive when compared to
healthy donor MSCs. Regardless of in vitro suppressive
capacity, results from this study were not significant enough
to draw conclusions on efficacy of MSCs in Crohn's disease. 2
patients saw clinical improvement of disease while 3
patients had to undergo surgery due to worsened disease
post infusion [56]. Results of these trials suggest the safety
of using MSC from both autologous and allogeneic donors
from possible treatment.
Notably, none of the MSC transplant studies to date in
humans have conclusively shown treatment related side ef-
fects. This indicates that MSC transplantation may be a ben-
eficial option for SLE, especially in patients refractory to
current available treatments. None of these studies, however,
were blinded or controlled and all patients continued to receive
standard therapy. Studies in animal models suggest that side
effects are plausible due to the multipotency of the MSCs.
Concerns regarding their safety include transformation into
osteoclasts in inappropriate locations, malignancy conversion,
etc. Thus, though the data for MSC transplantation in lupus is
hopeful, proof of efficacy remains to be proven in controlled
trials comparing standard therapy versus the addition of MSC.
Another concern is the possible tumor enhancing properties of
MSCs. The tumormicroenvironment often has a similar cytokine
profile to that of an area of tissue damage. This cytokine milieu
can attract MSCs to this area where they can elicit tumor
enhancing effects [57]. In vitro work has shown that MSCs
primed with IFNγ can induce the death of various tumor cell
lines. However, MSCs with or without IFNγ priming accelerated
tumor growth in vivo when co-transferred with tumor cell lines
into nude mice [26]. These results suggest that MSC therapy
would have to be reserved for patients that fit a specific list of
criteria, including no history of tumors.4. Future directionsIt is clear that MSC transplantation has the potential for
substantial therapeutic effects on patients with SLE. How-
ever, the mechanisms by which MSCs are eliciting their
suppressive effects in vivo are still not completely under-
stood. MSCs from various sources all appear to have immuno-
modulatory abilities albeit to varying degrees. Further
examination of MSCs must be done to discern the potency
of MSCs from these different sources. In addition to various
sources, investigation of MSCs from healthy and diseased
individuals must also be completed to determine if suppres-
sive efficacy is hindered when the MSCs are from an au-
toimmune donor. Although various studies support the
efficacy of autoimmune MSCs [56,58], conflicting results
require more studies to establish whether SLE disease
activity contributes to the reduction of suppressive capacity
that has been noted in SLE-MSC. The source and donor of
333Hematopoetic and mesenchymal stem cell transplantationMSCs will likely prove to be of importance as future studies
regarding MSC transplantation are performed.
MSCs require a particular microenvironment in order to
achieve maximum suppressive function. The appropriate
activation microenvironment of MSC requires additional
clarification since the environment that is essential to
activate MSCs is also the pro-inflammatory environment
that leads to the pathogenesis of autoimmune diseases.
Questions arise such as to what point MSC activation should
occur to promote their immuno-suppressive behavior once
transplanted. Furthermore, the patient's microenvironment
may need to be assessed before transplantation to predict
whether MSCs will retain suppressive function. Prediction of
what patients will respond best to MSC treatment in addition
to the initial efficacy of the MSCs is also something to be
examined. An in vitro MSC marker correlating to the in vivo
functionality of the cells is of particular need. Developing a
read out to indicate in vitro the MSCs in vivo suppressive
abilities will assist in determining what source/donor would
be optimal for transplantation into a particular patient.
Although further studies are necessary, current evidence
suggests that MSCs will become a successful option for the
treatment of SLE. Autologous hematopoetic stem cell trans-
plantation remains a viable option for patients with severe
disease refractory to standard therapy. Careful patient se-
lection and performance only in experienced centers are
crucial for proper use of this therapy.Conflict of interest statement
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